Neurocrine Biosciences has agreed to acquire Soleno Therapeutics for $2.9 billion, the companies said, in a deal designed to bolster the buyer’s portfolio of marketed endocrinology and rare disease ...

Gilead Sciences has agreed to acquire German-based Tubulis for up to $5 billion, the companies said today, in a deal designed to expand the buyer’s antibody–drug conjugate (ADC) capabilities with a ...

A new class of drug compounds, called ENDOtollins, reduce harmful inflammation while maintaining the body’s ability to fight infections.

Microplastics turned up in every human bile sample tested and pushed duct cells toward mitochondrial dysfunction and ...

Researchers suggest their approach has the potential to transform early disease detection and health monitoring across diverse clinical settings.

The integrated approach is designed to adapt to the evolving needs of new therapeutic modalities, delivering both speed and performance.

A new metabolic mechanism describes how tumors disable “gatekeeper” cells to prevent immune response to cancer.

Directly transferring healthy mitochondria or cytoplasmic components into target cells is particularly relevant for regenerative medicine.

FDA approval of the first organoid-supported IND application augurs a future in which new approach methodologies supplant animal testing.

Eli Lilly has won FDA approval for its oral obesity drug Foundayo™ (orforglipron), but the stock bounce was short lived as ...

Study findings indicate that environmentally relevant doses of OLA bioplastics may be “more toxic” to the placenta than ...

From a chemistry, manufacturing, and controls (CMC) perspective, ADCs present unique hurdles. “ADCs introduce unique challenges across areas like process and purification development, analytical ...